PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced that PharmaBlock Zhejiang manufacturing site successfully passed pre-approval inspection (PAI) and dynamic inspection for GMP compliance by the China National Medical Products Administration (NMPA) for an API product.
PharmaBlock Zhejiang, as the drug substance production base of PharmaBlock, has consistently demonstrated exceptional quality and compliance standards. It has undergone thorough inspections by both the US FDA and the China NMPA, maintaining an exemplary track record. This recognition further showcases PharmaBlock's comprehensive capabilities and highlights its commitment to stringent quality management and compliant production practices.
"This approval is a testament to our continuous efforts in building a robust quality system and maintaining compliant manufacturing processes," emphasized Dr. Minmin Yang, Founder and CEO of PharmaBlock, "We will continue to adhere to strict quality management standards, ensuring that we offer the high-quality manufacturing solutions and create even greater value for our partners. With our ongoing commitment to innovation, we aim to expedite the introduction of innovative drugs to the market and make significant contributions to human health."